NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

Thank you very much for answering my post. I am less stressed now I have read you answer and even more confident DCVAX L is a winner.

Methylated mgmt + idh-1 mutant are extremely long lived when combined

My take what you posted:
Previous GBM trials with ONLY Methylated MGMT mOS was 21.2 months (from randomization***). The Checkmate 548's placebo survival mOS improved to 32.1 months not because of the improvement of surgery/chemo/radiation (aka SOC) as someone suggested but because Methylated mgmt PLUS idh-1 mutant (in the Checkmate 548's placebo survival) are extremely long lived.
The reason why I personally find this is incredibly relevant for the DCVAX L trial is because if the increase of the Checkmate 548 mOS compared to other Methylated mgmt SOC had been induced by improvement of SOC then that, as of 2 weeks ago, could have caused problems for the KOLS to compare L trial results to SOC as we have known it over the last years. But its a relief to read its not.

Even when comparing apples Methylated mgmt +] idh-1 mutant with Oranges DCVAX L unblinded trial results, mOS of DCVAX L will likely improve significantly. Also, as someone mentioned here the Checkmate trial in the end reported an OS of 5% after 3 (?) years. Well, the DCVAX L trial will beat those results multiple times which is in the end the golden standard.